Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium

Supportive Care in Cancer

Volumn 16, Issue 8, 2008, Pages 905-915

  Annemans, Lieven ^a   Strens, Daniëlle ^b   Lox, Erica ^c   Petit, Christine ^c   Malonne, Hughes ^c  

^a GHENT UNIVERSITY   (Belgium)

^b IQVIA   (United States)

^c Merck Sharp and Dohme   (Belgium)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Emetogenic chemotherapy regimens

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ONDANSETRON; PLACEBO;

ARTICLE; BELGIUM; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMBINATION CHEMOTHERAPY; COMPUTER PROGRAM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; NAUSEA AND VOMITING; NEOPLASM; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BELGIUM; CISPLATIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DRUG COSTS; HUMANS; MORPHOLINES; NAUSEA; VOMITING;

EID: 48249086944     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0349-1     Document Type: Article

References (27)

1. A Coates S Abraham SB Kaye 1983 On the receiving end: patient perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 203 208
2. M de Boer-Dennert R de Wit PI Schmitz J Djontono V v Beurden G Stoter J Verweij 1997 Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists Br J Cancer 76 8 1055 1061
3. Aapro M. S., H. J. Schmoll, S. Poli-Bigelli, K. Jordan, J. von Pawel, H. Giezek, T. Ahmed, C. Y. Chan (2005) Comparison of aprepitant combination regimen with 4-day ondansetron +4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy. Abstract No: 8007, ASCO Annual Meeting
4. AM Griffin PN Butow AS Coates AM Childs PM Ellis SM Dunn MH Tattersall 1996 On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 2 189 195
5. A Ihbe-Heffinger B Ehlken R Bernard K Berger C Peschel HG Eichler R Deuson J Thodtmann F Lordick 2004 The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers Ann Oncol 15 3 526 536
6. HJ Schmoll MS Aapro S Poli-Bigelli HK Kim K Park K Jordan J von Pawel H Giezek T Ahmed CY Chan 2006 Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Ann Oncol 17 6 1000 1006
7. J Herrstedt HB Muss DG Warr PJ Hesketh PD Eisenberg H Raftopoulos SM Grunberg M Gabriel A Rodgers CM Hustad KJ Horgan F Skobieranda 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. (Trial 071 multiple cycles) Cancer 104 7 1548 1555
8. PJ Hesketh SM Grunberg RJ Gralla DG Warr F Roila R de Wit SP Chawla AD Carides J Ianus ME Elmer JK Evans K Beck S Reines KJ Horgan Aprepitant Protocol 052 Study Group 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin J Clin Oncol 21 22 4112 4119
9. S Poli-Bigelli J Rodrigues-Pereira AD Carides G Julie Ma K Eldridge A Hipple JK Evans KJ Horgan F Lawson Aprepitant Protocol 054 Study Group 2003 Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 12 3090 3098
10. R de Wit J Herrstedt B Rapoport AD Carides J Guoguang-Ma M Elmer C Schmidt JK Evans KJ Horgan 2004 The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials Eur J Cancer 40 3 403 410
11. F Lordick B Ehlken A Ihbe-Heffinger K Berger KJ Krobot J Pellissier G Davies R Deuson 2007 Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany Eur J Cancer 43 2 299 307
12. C Sun D Bodurka M Donato E Rubenstein C Borden K Basen-Engquist M Munsell J Kavanagh D Gershenson 2002 Patient preferences regarding side effects of chemotherapy for ovarian cancer: Do they change over time? Gynecol Oncol 87 1 118 120
13. S Borjeson TJ Hursti C Peterson M Fredikson CJ Furst E Avall-Lundqvist G Steineck 1997 Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale Cancer Nurs 20 4 260 266
14. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
15. C Seynaeve J Schuller K Buser H Porteder S Van Belle P Sevelda D Christmann M Schmidt H Kitchener D Pacs PHM de Mulder on behalfof the Ondansetron Study Group 1992 Comparison of the antiemetic efficacyof ondansetron given as either a continuousinfusion or a single intravenousdose, in acute cisplatin-induced emesis.A multicenter, double-blind, randomized,parallel group study Br J Cancer 66 192 197
16. Italian Group for Antiemetic Research (IGAR) 1995 Ondansetron versus granisetron, both combined with dexamethasone,in the prevention of cisplatin-induced emesis Ann Oncol 6 805 810
17. Ruff P, Paska W, Goedhals L, Pouiliart P, Riviere A, on behalf of the GranisetronStudy GroupVorolieof D, Bloch B, Jones A, Martin L, Brunet R, Butcher, Forster J, McQuade B, on behalf of theOndansetron and Granisetron EmesisStudy Group (1994) Ondansetron compared with granisetron in the prophylaxisof cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 51:113-118
18. SM Grunberg RR Deuson P Mavros O Geling M Hansen G Cruciani B Daniele G De Pouvourville EB Rubenstein G Daugaard 2004 Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 10 2261 2268
19. DG Warr PJ Hesketh RJ Gralla HB Muss J Herrstedt PD Eisenberg H Raftopoulos SM Grunberg M Gabriel A Rodgers N Bohidar G Klinger CM Hustad KJ Horgan F Skobieranda 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 12 2822 2830
20. MC Weinstein 2006 Recent developments in Decision-Analytic Modelling for Economic Evaluation PharmacoEconomics 24 4 1043 1053
21. G Dranitsaris P Leung 2004 Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy Int J Technol Assess Health Care 20 3 289 295
22. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Susan Groshen, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. JCO 2971, Sep 1
23. MG Kris PJ Hesketh MR Somerfield P Feyer R Clark-Snow JM Koeller GR Morrow LW Chinnery MJ Chesney RJ Gralla SM Grunberg 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 18 2932 2947
24. Cancer Care Ontario: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Toronto, 1999
25. Geling O, Eichler HG. Should 5-Hydroxytryptamine-3 Receptor Antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. JCO, 2005, Feb, 23, 6
26. CA Uyl-de Groot S Wait I Buijt 2000 Economics and health-related quality of life in antiemetic therapy: recommendations for trial design Eur J Cancer 36 12 1522 1535
27. J Lachaine C Laurier 2002 Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy Am J Health Syst Pharm 59 19 1837 1846